You may already have a page of tirzepatide questions: the first payment, the pharmacy name, or whom to contact after a visit. A broader peptide announcement can make that page feel unfinished again. Before changing your questions, write down which part of the announcement appears to answer one of them. Then check the connection.
The Federal Register notice describes conditional 503A enforcement discretion during bulks-list rulemaking for state-licensed pharmacies, federal facilities and licensed physicians. It calls the policy draft and nonbinding. A 503A notice does not establish a final bulks-list entry or 503B eligibility. At our October 30, 01:30 US/Eastern check, publication remained scheduled for October 30 but was unverified. That does not establish nonpublication, and we have not established an effective date.[2]
Start with the named preparation
| Preparation | Route |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral or topical |
| TB-500 acetate | Subcutaneous or intramuscular |
| Epitalon acetate | Subcutaneous or intramuscular; intermittent courses |
| Semax free base | Intranasal |
| KPV acetate | Oral or topical |
| MOTS-c acetate | Subcutaneous or intramuscular |
Read the requirements as a set[1]
- Appendix A membership.
- Appendix B identity (sequence, structure, molecular weight/formula) and route limits.
- Section 510 registered facility; valid certificate of analysis (COA): Appendix B identity, purity, potency and contaminant testing.
- Original bulk manufacturer: section 510 registration, CGMP/FD&C compliance, physical address on COA; registered intermediaries document manufacturer/COA validation.
- Report products, serious adverse events regardless of causation, and quality issues to FDA and compounding/destination States; MedWatch for events/quality; label reporting procedures. Product reports identify ingredient/strength per unit, original manufacturer/unique facility identifier, dosage form/route.
- Label: “This is a compounded drug product. Not for resale.”
- Only one active ingredient in the entire product, listed in Appendix A.
- Oral: document adequate human bioavailability of the supplied formulation.
- Co-packaged/containing delivery device: only an FDA 510(k)-cleared syringe.
- Remaining FD&C rules, sanitary conditions and patient-specific prescriptions.
Name the object of the claim
FDA's compounding explanation makes two distinctions worth keeping visible. Compounded medicines are not FDA-approved, and an approved generic is a different category. For the finished product, drugs compounded in accordance with 503A are exempt from current good manufacturing practice (CGMP) requirements; outsourcing-facility drugs are subject to them.[4]
On your notebook page, give each document a subject: the ingredient supplier, the finished preparation, or the service arranging care. Avoid letting a statement about one stand in for an answer about another. Beside it, write the exact question that remains open. This makes the conversation easier to continue even when everyone is using the same reassuring word.
For a hypothetical example, suppose a service answers a question about follow-up by sending a manufacturing document. Keep the document, but restate the question: who will respond, through which channel, and when? Asking for the missing answer is more useful than deciding that the document must either settle everything or be worthless.
Give the company announcement its own line
On October 29, Hims & Hers previewed Peptides+ with a waitlist. Its planned menu includes sermorelin, glutathione, B12, NAD+ and L-carnitine, spanning peptides and other therapies. It places BPC-157 and TB-500 later, when allowable. This announcement does not verify current dispensing, eligibility where you live, prices or clinical benefits.[3]
A useful comparison needs the same kind of information on both sides. If one column holds a dated plan and the other holds an offer sent to you, label them that way before comparing. Leave an unanswered space where necessary. Filling it with an assumption can make a comparison look complete while making your next conversation less precise.
Keep the earlier fieldnotes beside this one
We have kept the existing tirzepatide compounding guide and the library's clinical fields intact. This update adds a policy discussion; it does not reassess the underlying clinical evidence, refresh provider prices or decide whether a particular prescription qualifies. Use the earlier pages to recover the question you were originally trying to answer.
When preparing for a visit, choose one unresolved point rather than copying the whole announcement into your notes. Keep the source title and date beside that point, and ask what information would be needed to answer it for your circumstances. You can then record the answer without confusing it with a promise made somewhere else.
Reader questions
Where does the older BPC-157 study description belong?
The existing entry keeps its October 27 source dates and intravenous-study context. Place that historical record beside this policy table, with each route attached to its own document. We have not reassessed the study or replaced the entry's clinical fields.
What should I do with an unclear condition?
Keep it as a question for the responsible professional, with the original text available. This reading note supplies no device exception, reporting timetable, dose or formulation-specific compliance finding. We have not inspected chemical drawings, supplier certificates or pharmacy operations.
Sources
- HHS policy
HHS · Checked
- Federal Register notice
HHS · Checked
- Peptides+ preview
Hims & Hers · Checked
- Compounding Q&A
FDA · Checked